Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7813105 | 0.79 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL9217667 | 0.78 | MAPT (0.47) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL9226507 | 0.76 | MAPT (0.45) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL18084487 | 0.74 | MGAM (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL9712158 | 0.74 | MAPT (0.48) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL25284860 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL6833296 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL852172 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL10523358 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 | |
| SCHEMBL2007179 | 0.74 | MAPT (0.44) | MAPTESR1ESR2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103221382-B | Preparation pet precursor | GE HEALTHCARE LTD. (GB) | 2016-06-01 | — | — | CN | claimed |
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-06-24 | — | — | US | claimed |
| EP-2004651-A2 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007115620-A2 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | claimed |
| CN-113677364-A | Pharmaceutical compositions comprising anti-191P 4D12 antibody drug conjugates and methods of use thereof | 艾更斯司股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3775203-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020124188-A1 | POLYPEPTIDE WITH ASPARAGINASE ACTIVITY, POLYNUCLEOTIDE, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, METHODS FOR PRODUCING A POLYPEPTIDE WITH ASPARAGINASE ACTIVITY AND FOR PREVENTING OR TREATING NEOPLASMS, AND USE OF A POLYPEPTIDE | FUNDAÇÃO OSWALDO CRUZ (BR) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019200185-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-10-17 | — | — | WO | disclosed |
| CN-110248676-A | Combination treatment | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110234342-A | Combination treatment | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-110225983-A | Methods of treating cancer | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-110225914-A | Bicyclic urea kinase inhibitor and application thereof | 布罗德研究所股份有限公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-1473043-A | A method for treating allergy by using substituted pyrazole | ����-������ҩƷ��˾ | 2004-02-04 | — | — | CN | disclosed |
| CN-1373660-A | Method for treating chronic pain using MEK inhibitors | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | CN | disclosed |
| CN-1365277-A | Methods of treating chronic pain using MEK inhibitors | VARNER LAMBERT CO (US) | 2002-08-21 | — | — | CN | disclosed |
| CN-1358095-A | Methods of treating chronic pain using MEK inhibitors | WARNER LAMBERT CO (US) | 2002-07-10 | — | — | CN | disclosed |
| CN-1358094-A | Methods of treating chronic pain with MEK inhibitors | WARNER LAMBERT CO (US) | 2002-07-10 | — | — | CN | disclosed |
| CN-1348373-A | Use of 17-ketosteroids for the treatment of malaria and Trypanosomiasis | HOLLIS EDEN PHARMACEUTICALS (US) | 2002-05-08 | — | — | CN | disclosed |
| CN-1328463-A | Use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors for treatment of hapatitis C type virus and other togavirus infections | HOLLIS EDEN PHARMACEUTICALS (US) | 2001-12-26 | — | — | CN | disclosed |
| CN-1238762-A | Piperidine compounds | GILEAD SCIENCES INC (US) | 1999-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | MAPT 1828/4885ESR1 3514/4885ESR2 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.